Table 1 Clinical characteristics of patients in both treatment groups
Parameters | Tofogliflozin group | Conventional group | P value |
|---|---|---|---|
Sex (males) (%) | 99 (58.6) | 99 (58.2) | 1.00 |
Age (years) | 61.3 ± 9.3 | 60.9 ± 9.7 | 0.66 |
Current smoking | 38 (22.6) | 29 (17.1) | 0.22 |
Hypertension | 88 (52.1) | 105 (61.8) | 0.08 |
Dyslipidemia | 107 (63.3) | 122 (71.8) | 0.11 |
Duration of diabetes (years) | 12.1 ± 8.4 | 12.5 ± 8.3 | 0.65 |
Diabetic retinopathy | 28 (16.8) | 33 (19.5) | 0.51 |
Diabetic nephropathy | 48 (28.4) | 53 (31.2) | 0.58 |
Use of glucose-lowering agents | 153 (90.5) | 152 (89.4) | 0.86 |
 Metformin | 91 (53.8) | 100 (58.8) | 0.38 |
 Sulfonylurea | 38 (22.5) | 43 (25.3) | 0.61 |
 Glinides | 10 (5.9) | 10 (5.9) | 1.00 |
 Thiazolidinediones | 18 (10.7) | 23 (13.5) | 0.51 |
 α-Glucosidase inhibitor | 24 (14.2) | 25 (14.7) | 1.00 |
 DPP-4 inhibitors | 75 (44.4) | 95 (55.9) | 0.039 |
 GLP-1 R agonists | 23 (13.6) | 12 (7.1) | 0.05 |
 Insulins | 35 (20.7) | 37 (21.8) | 0.89 |
Use of antihypertensive drugs | 79 (46.7) | 95 (55.9) | 0.10 |
 Angiotensin-converting enzyme inhibitors | 3 (1.8) | 5 (2.9) | 0.72 |
 Angiotensin II receptor blockers | 63 (37.3) | 83 (48.8) | 0.037 |
 Direct renin inhibitor | 2 (1.2) | 0 (0.0) | 0.25 |
 Calcium channel blocker | 47 (27.8) | 54 (31.8) | 0.48 |
 Diuretic drugs | 8 (4.7) | 14 (8.2) | 0.27 |
 α-Adrenergic receptor antagonist | 2 (1.2) | 0 (0.0) | 0.25 |
 β-Adrenergic receptor antagonist | 3 (1.8) | 3 (1.8) | 1.00 |
 Others | 5 (3.0) | 10 (5.9) | 0.29 |
Use of lipid-lowering agents | 82 (48.5) | 99 (58.2) | 0.08 |
 Statins | 73 (43.2) | 83 (48.8) | 0.33 |
 Ezetimibe | 10 (5.9) | 11 (6.5) | 1.00 |
 Resins | 0 (0.0) | 1 (0.6) | 1.00 |
 Fibrates | 8 (4.7) | 6 (3.5) | 0.60 |
Use of antithrombotic agents | 17 (10.1) | 15 (8.8) | 0.71 |
 Antiplatelet agents | 15 (8.9) | 11 (6.5) | 0.42 |
 Anticoagulants | 2 (1.2) | 4 (2.4) | 0.68 |
 Others | 0 (0.0) | 0 (0.0) | – |